Guhan Pharmaceutical Group Co

Guhan Pharmaceutical Group Co Interest Coverage

The Interest Coverage Ratio of Guhan Pharmaceutical Group Co (000590.SZ) as of Oct 30, 2026 is -58.37. In the previous year, Interest Coverage Ratio was 39.52 — a change of -247.69% (lower).

Interest Coverage

-58.37

YoY

-247.69%

Last updated:

Interest Coverage Ratio of Guhan Pharmaceutical Group Co is 2024 -58.37 . Interest Coverage Ratio of Guhan Pharmaceutical Group Co was 2023 39.52 . It decreases by -247.69% lower compared to the previous year.

The Guhan Pharmaceutical Group Co Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
6.38 CNY
Jan 1, 2018
-6.66 CNY
Jan 1, 2019
28.95 CNY
Jan 1, 2020
5.79 CNY
Jan 1, 2021
5.88 CNY
Jan 1, 2022
4.48 CNY
Jan 1, 2023
39.52 CNY
Jan 1, 2024
-58.37 CNY
The Guhan Pharmaceutical Group Co Interest Coverage history
YEARInterest CoverageYoY
-58.37-247.69%
39.52+781.53%
4.48-23.78%
5.88+1.60%
5.79-80.00%
28.95-534.84%
-6.66-204.41%
6.38-74.47%
24.97+2.84%
24.28-180.00%
-30.35—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Guhan Pharmaceutical Group Co Stock analysis

What does Guhan Pharmaceutical Group Co do? Tus-Pharmaceutical Group Co., Ltd. generates revenue through the research and development, production, and sales of Chinese patent medicine and western medicine preparations. The company offers Chinese healthcare products, cold treatment medicines, and anti hyperlipemia medicines, alongside western medicine products such as clindamycin phosphate for injection, lomefloxacin hydrochloride for injection, and levofloxacin lactate for injection. Domestic markets are the primary sales channel for all products. The firm's revenue streams are derived from the sale of these pharmaceutical products to domestic customers. The company focuses on Chinese patent medicine, including healthcare products, cold treatment remedies, and anti hyperlipemia treatments. Western medicine preparations like clindamycin phosphate for injection, lomefloxacin hydrochloride for injection, and levofloxacin lactate for injection form a significant part of its product portfolio. These products are distributed exclusively within China, targeting domestic consumers and healthcare providers. Tus-Pharmaceutical Group Co., Ltd. serves domestic markets with its range of Chinese and western medicines. The company's product lines include Chinese healthcare products, cold treatment medicines, anti hyperlipemia medicines, and specific western medicine injections. Sales are conducted within China, with no mention of international distribution. The firm's revenue is generated through the direct sale of these pharmaceutical products to domestic buyers. Guhan Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guhan Pharmaceutical Group Co stock

Interest Coverage Ratio of Guhan Pharmaceutical Group Co is -58.37 in 2024.

Interest Coverage Ratio of Guhan Pharmaceutical Group Co changed from 39.52 to -58.37, representing a -247.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Guhan Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Guhan Pharmaceutical Group Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Guhan Pharmaceutical Group Co

All Key Metrics — Guhan Pharmaceutical Group Co